Unlocking the potential of organoids in cancer treatment and translational research: An application of cytologic techniques
- PMID: 37843532
- DOI: 10.1002/cncy.22769
Unlocking the potential of organoids in cancer treatment and translational research: An application of cytologic techniques
Abstract
Patient-derived organoid models hold promise for advancing clinical cancer research, including diagnosis and personalized and precision medicine approaches, and cytology, in particular, plays a pivotal role in this process. These three-dimensional multicellular structures are heterogeneous, potentially maintain the cancer phenotype, and conserve the genomic, transcriptomic, and epigenomic patterns of the parental tumors. To ensure that only tumor tissue is used for organoid development, cytologic validation is necessary before initiating the process of organoid generation. Here, we explore the technology of tumor organoids and discuss the fundamental application of cytology as a simple and cost-effective approach toward organoid development. We also underscore the potential application of organoid development in drug efficacy studies for lung cancer and head and neck tumors. Additionally, we stress the importance of using fine-needle aspiration to generate tumoroids.
Keywords: cytology smears; head and neck cancer; lung cancer; organoids; personalized and precision medicine; rare tumors; tumoroids.
© 2023 American Cancer Society.
Similar articles
-
On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study.Anticancer Res. 2017 Apr;37(4):1569-1573. doi: 10.21873/anticanres.11486. Anticancer Res. 2017. PMID: 28373416
-
Progress and perspective of organoid technology in cancer-related translational medicine.Biomed Pharmacother. 2022 May;149:112869. doi: 10.1016/j.biopha.2022.112869. Epub 2022 Mar 28. Biomed Pharmacother. 2022. PMID: 35358798 Review.
-
An emerging role for cytopathology in precision oncology.Cancer Cytopathol. 2016 Mar;124(3):167-73. doi: 10.1002/cncy.21647. Epub 2015 Dec 7. Cancer Cytopathol. 2016. PMID: 26641771
-
Organoid models of breast cancer in precision medicine and translational research.Mol Biol Rep. 2024 Nov 21;52(1):2. doi: 10.1007/s11033-024-10101-x. Mol Biol Rep. 2024. PMID: 39570495 Review.
-
[Application of Organoids in Lung Cancer Precision Medicine].Zhongguo Fei Ai Za Zhi. 2020 Jul 20;23(7):615-620. doi: 10.3779/j.issn.1009-3419.2020.101.20. Zhongguo Fei Ai Za Zhi. 2020. PMID: 32702796 Free PMC article. Review. Chinese.
Cited by
-
Prognostic models for immunotherapy in non-small cell lung cancer: A comprehensive review.Heliyon. 2024 Apr 17;10(8):e29840. doi: 10.1016/j.heliyon.2024.e29840. eCollection 2024 Apr 30. Heliyon. 2024. PMID: 38681577 Free PMC article. Review.
-
Extraenteric Malignant Gastrointestinal Neuroectodermal Tumor of the Neck: A Diagnostic Challenge.Int J Mol Sci. 2025 May 9;26(10):4517. doi: 10.3390/ijms26104517. Int J Mol Sci. 2025. PMID: 40429661 Free PMC article. Review.
-
Recent advances and challenges in colorectal cancer: From molecular research to treatment.World J Gastroenterol. 2025 Jun 7;31(21):106964. doi: 10.3748/wjg.v31.i21.106964. World J Gastroenterol. 2025. PMID: 40538516 Free PMC article. Review.
-
Harnessing Organoid Platforms for Nanoparticle Drug Development.Drug Des Devel Ther. 2025 Jul 18;19:6125-6143. doi: 10.2147/DDDT.S530999. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 40698061 Free PMC article. Review.
References
REFERENCES
-
- Schütte M, Risch T, Abdavi-Azar N, et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun. 2017;8(1):14262. doi:10.1038/ncomms14262
-
- Nam C, Ziman B, Sheth M, Zhao H, Lin DC. Genomic and epigenomic characterization of tumor organoid models. Cancers. 2022;14(17):4090. doi:10.3390/cancers14174090
-
- Kondo J, Inoue M. Application of cancer organoid model for drug screening and personalized therapy. Cells. 2019;8(5):470. doi:10.3390/cells8050470
-
- Zhao Z, Chen X, Dowbaj AM, et al. Organoids. Nat Rev Methods Primers. 2022;2(1):94. doi:10.1038/s43586-022-00174-y
-
- Chai C, Ji P, Xu H, et al. Targeting cancer drug resistance utilizing organoid technology. Biomed Pharmacother. 2023;158:114098. doi:10.1016/j.biopha.2022.114098
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical